Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Ovarian conservation for young women with clinical stage IB-IIB cervical cancer in Japan.

Matsuo K, Shimada M, Mikami M.

J Gynecol Oncol. 2017 Jul;28(4):e60. doi: 10.3802/jgo.2017.28.e60. No abstract available.

2.

Molecular signature of anastasis for reversal of apoptosis.

Tang HM, Talbot CC Jr, Fung MC, Tang HL.

Version 2. F1000Res. 2017 Jan 13 [revised 2017 Feb 9];6:43. doi: 10.12688/f1000research.10568.2. eCollection 2017.

3.

Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa.

Goeieman BJ, Firnhaber CS, Jong E, Michelow P, Kegorilwe P, Swarts A, Williamson AL, Allan B, Smith JS, Wilkin TJ.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):e59-e64. doi: 10.1097/QAI.0000000000001300.

PMID:
28141783
4.

Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects.

Gilbert ES, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni JF Jr, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman P, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, van Leeuwen FE.

Radiat Res. 2017 Feb;187(2):186-195. doi: 10.1667/RR14453.1. Epub 2017 Jan 24.

PMID:
28118119
5.

Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone.

Chiou WY, Chen CA, Lee MS, Lin HY, Li CY, Su YC, Tsai SJ, Hung SK.

Medicine (Baltimore). 2016 Nov;95(47):e5409.

6.

Is there a role for IGF-1 in the development of second primary cancers?

Shanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M.

Cancer Med. 2016 Nov;5(11):3353-3367. doi: 10.1002/cam4.871. Epub 2016 Oct 13. Review.

7.

HMGB1 interacts with XPA to facilitate the processing of DNA interstrand crosslinks in human cells.

Mukherjee A, Vasquez KM.

Nucleic Acids Res. 2016 Feb 18;44(3):1151-60. doi: 10.1093/nar/gkv1183. Epub 2015 Nov 17.

8.

Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study.

Teng CJ, Huon LK, Hu YW, Yeh CM, Chao Y, Yang MH, Chen TJ, Hung YP, Liu CJ.

Medicine (Baltimore). 2015 Oct;94(43):e1803. doi: 10.1097/MD.0000000000001803.

9.

Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE.

Br J Radiol. 2015;88(1056):20150405. doi: 10.1259/bjr.20150405. Epub 2015 Oct 14. Review.

10.

Second Primary Cancer after Diagnosis and Treatment of Cervical Cancer.

Lim MC, Won YJ, Lim J, Kim YJ, Seo SS, Kang S, Lee ES, Oh JH, Kim JY, Park SY.

Cancer Res Treat. 2016 Apr;48(2):641-9. doi: 10.4143/crt.2014.326. Epub 2015 Jul 17.

11.

Screening for Anal Cancer in Women.

Moscicki AB, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, Chiao E, Einstein MH, Goldstone SE, Jay N, Likes WM, Stier EA, Welton ML, Wiley DJ, Palefsky JM.

J Low Genit Tract Dis. 2015 Jul;19(3 Suppl 1):S27-42. doi: 10.1097/LGT.0000000000000117. Review.

12.

Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.

Ye J, Yin L, Xie P, Wu J, Huang J, Zhou G, Xu H, Lu E, He X.

Onco Targets Ther. 2015 May 26;8:1211-8. doi: 10.2147/OTT.S79899. eCollection 2015.

13.

Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review.

Stier EA, Sebring MC, Mendez AE, Ba FS, Trimble DD, Chiao EY.

Am J Obstet Gynecol. 2015 Sep;213(3):278-309. doi: 10.1016/j.ajog.2015.03.034. Epub 2015 Mar 19. Review.

14.

A rare case of eight multiple primary malignant neoplasms in a female patient: A case report and review of the literature.

Zhao J, Tan Y, Wu Y, Zhao W, Wu J, Ji M, Shi L, Jiang J, Wu C.

Oncol Lett. 2015 Feb;9(2):587-590. Epub 2014 Dec 10.

15.

Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses.

Nguyen J, Moteabbed M, Paganetti H.

Med Phys. 2015 Jan;42(1):81-9. doi: 10.1118/1.4903272.

16.

Clinical epidemiology of epithelial ovarian cancer in the UK.

Doufekas K, Olaitan A.

Int J Womens Health. 2014 May 23;6:537-45. doi: 10.2147/IJWH.S40894. eCollection 2014. Review.

17.

FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells.

Liu XL, Meng YH, Wang JL, Yang BB, Zhang F, Tang SJ.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1534-43. eCollection 2014.

18.

A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.

Sun Y, Myers CJ, Dicker AP, Lu B.

PLoS One. 2014 Feb 18;9(2):e87492. doi: 10.1371/journal.pone.0087492. eCollection 2014.

19.

The effect of patient characteristics on second primary cancer risk in France.

Jégu J, Colonna M, Daubisse-Marliac L, Trétarre B, Ganry O, Guizard AV, Bara S, Troussard X, Bouvier V, Woronoff AS, Velten M.

BMC Cancer. 2014 Feb 15;14:94. doi: 10.1186/1471-2407-14-94.

20.

Solid tumor second primary neoplasms: who is at risk, what can we do?

Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS.

Semin Oncol. 2013 Dec;40(6):676-89. doi: 10.1053/j.seminoncol.2013.09.012. Review.

Supplemental Content

Support Center